GlobeNewswire

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux^[1]

Press Release Nicox: Half-year liquidity contract statement with Kepler Cheuvreux   January 11, 2021 – release at 7:30 am CET Sophia Antipolis, France                                                                     Under the liquidity contract entered into between Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st, 2020:   –    147,145 shares –    € 394,966.53   –    Number of executions on buy side on semester: 829 –    Number of executions on sell side on semester: 609 –    Traded volume on buy side on semester: 457,955 shares for € 1,916,480.01   –    Traded volume on sell side on semester: 310,810 shares for € 1,312,111.94   As a reminder :   •    the following resources appeared on the liquidity account when the activity started:   –    0 shares –    € 500,000.00   The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.           About Nicox Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox’s lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.  The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.  Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.  Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com. Analyst coverage   Bryan, Garnier & Co        Victor Floc’h           Paris, France Cantor Fitzgerald             Louise Chen           New York, U.S. H.C. Wainwright & Co      Yi Chen                   New York, U.S. Kepler Cheuvreux             Damien Choplain   Paris, France Oppenheimer & Co          Hartaj Singh            New York, U.S.  The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current.  Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts Nicox Gavin Spencer Executive Vice President, Chief Business Officer & Head of Corporate Development  T +33 (0)4 97 24 53 00 communications@nicox.com Investors & Media United States & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 853 mchang@lifesciadvisors.comMedia France LifeSci Advisors, LLC Sophie Baumont M +33 (0)6 27 74 74 49 sophie@lifesciadvisors.com Forward-Looking Statements The information contained in this document may be modified without prior notice.  This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance.  These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which is available on Nicox’s website (www.nicox.com) and in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox’s website.. Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99  Attachment * EN_Kepler – Half yearly liquidity contract statement PR_20210108_1

Read Article to Me (Mobile Version)

Source URL: Read More
The public content above was dynamically discovered – by graded relevancy to this site’s keyword domain name. Such discovery was by systematic attempts to filter for “Creative Commons“ re-use licensing and/or by Press Release distributions. “Source URL” states the content’s owner and/or publisher. When possible, this site references the content above to generate its value-add, the dynamic sentimental analysis below, which allows us to research global sentiments across a multitude of topics related to this site’s specific keyword domain name. Additionally, when possible, this site references the content above to provide on-demand (multilingual) translations and/or to power its “Read Article to Me” feature, which reads the content aloud to visitors. Where applicable, this site also auto-generates a “References” section, which appends the content above by listing all mentioned links. Views expressed in the content above are solely those of the author(s). We do not endorse, offer to sell, promote, recommend, or, otherwise, make any statement about the content above. We reference the content above for your “reading” entertainment purposes only. Review “DMCA & Terms”, at the bottom of this site, for terms of your access and use as well as for applicable DMCA take-down request.